Hemab Therapeutics(NASDAQ) COAG

Market Cap$2.09B

Since IPO (2026)+32%

5 YearN/A

1 YearN/A

1 Month+22%

$44.74

-5.33%

-2.52Today

Hemab Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 44.75	2026-07-29

Hemab Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.1%	USD 49.23	2026-07-22
1 month	+21.84%	USD 36.73	2026-06-29
Since inception	+31.62%	USD 34.00	2026-05-01

Hemab Therapeutics Financials at a Glance

Market Cap

$2.09B

Revenue (TTM)

$0.00

Net Income (TTM)

-$37.99

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

4.37 (High)

Dividend

$0.00

Beta (Volatility)

4.37 (High)

Price

$44.74

Volume

517,591.032

Open

$48.78

Price

$44.74

Volume

517,591.032

Open

$48.78

Previous Close

$44.75

Daily Range

$43.99 - $48.85

52-Week Range

$18.00 - $52.15

Estimated Earnings Date

Aug 20, 2026

Dividend

$0.00

Beta (Volatility)

4.37 (High)

Price

$44.74

Volume

517,591.032

Open

$48.78

Previous Close

$44.75

Daily Range

$43.99 - $48.85

52-Week Range

$18.00 - $52.15

Estimated Earnings Date

Aug 20, 2026

COAG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm focused on transforming the treatment of blood coagulation disorders. With operations in the United States and Denmark, the company aims to enhance patient life through innovative therapies.

Products and Services

HMB-001: A bispecific antibody in Phase 1/2 trials for Glanzmann thrombasthenia
HMB-002: A monovalent antibody for Von Willebrand disease in Phase 1/2 development
Various preclinical and discovery-stage programs targeting blood disorders

Growth Outlook

Pipeline candidates are advancing through critical clinical trial phases
Strong focus on innovative therapies for unmet medical needs
Established in 2020, the company is positioned for future growth

Financial Highlights

Recent quarterly revenue of $0, reflecting ongoing development phase
Cash and short-term investments total $163.5 million, providing operational runway
Net income for Q1 2026 was a loss of $22.7 million, typical for clinical-stage firms

Hemab Therapeutics Holdings, Inc. is dedicated to addressing significant medical needs in blood coagulation disorders. The company's leading candidates, HMB-001 and HMB-002, are in advanced clinical trials, showcasing the potential for impactful therapies. With a robust cash position, Hemab is well-equipped to navigate the challenges of clinical development. The focus on innovative solutions positions the company favorably within the biotechnology sector, appealing to investors interested in transformative healthcare advancements.

AI Generated • Jul 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Benny Sorensen, MD, PhD

Website

www.hemab.com

Headquarters

Cambridge, MA 02142, US

COAG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

36.18%

Return on Capital

N/A

Return on Assets

-32.81%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.09B

Shares Outstanding

46.71M

Volume

517.59K

Avg. Volume

361.43K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$23.61M

EBITDA

-$23.54M

Operating Cash Flow

-$21.58M

Capital Expenditure

-$112.00K

Free Cash Flow

-$21.70M

Cash & ST Invst.

$163.53M

Total Debt

$1.06M

Hemab Therapeutics Performance Analysis

Hemab Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Hemab Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2026-03-31	N/A

Hemab Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2024	2024-12-31	USD -24.25	N/A
2025	2025-12-31	USD -31.82	31.2%

Hemab Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2026-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.09B

N/A

Market Cap/Employee

$35.42M

N/A

Employees

N/A

Net Income

-$22.69M

N/A

EBITDA

-$23.54M

N/A

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$163.53M

N/A

Total Debt

$1.06M

N/A

Accounts Receivable

$1.43M

N/A

Inventory

$0.00

N/A

Long Term Debt

$519.00K

N/A

Short Term Debt

$544.00K

N/A

Return on Assets

-32.81%

N/A

Return on Invested Capital

-38.09%

N/A

Free Cash Flow

-$21.70M

N/A

Operating Cash Flow

-$21.58M

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,401.99-0.00%

^DJIDJI

^DJIDJI$51,943.58-0.02%

^IXICNASDAQ

^IXICNASDAQ$24,815.43-0.00%

BTCBitcoin

BTCBitcoin$64,239.00+0.01%

SPCXSPCX

SPCXSPCX$115.16-0.01%

AAPLAAPL

AAPLAAPL$343.83+0.01%

AMZNAMZN

AMZNAMZN$231.40+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$19.63-0.20%

NOKNokia

NOKNokia$8.41-0.06%

SKHYSK Hynix

SKHYSK Hynix$126.79-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$6.74-0.06%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$49.44+0.06%

INTCIntel

INTCIntel$81.88-0.05%

Questions About COAG

What is the current price of Hemab Therapeutics?

Hemab Therapeutics is trading at $44.75 per share.

What is the 52-week range for Hemab Therapeutics?

Over the past 52 weeks, Hemab Therapeutics has traded between $18.00 and $52.15.

How much debt does Hemab Therapeutics have?

As of the most recent reporting period, Hemab Therapeutics reported total debt of $361.23M.

How much cash does Hemab Therapeutics have on hand?

Hemab Therapeutics reported $49.86M in cash and cash equivalents in its most recent financial results.

What is Hemab Therapeutics’s dividend yield?

Hemab Therapeutics does not currently have a dividend yield.

Hemab Therapeutics(NASDAQ) COAG

Hemab Therapeutics Financials at a Glance

COAG News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Hemab Therapeutics

COAG Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Hemab Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About COAG

What is the current price of Hemab Therapeutics?

What is the 52-week range for Hemab Therapeutics?

How much debt does Hemab Therapeutics have?

How much cash does Hemab Therapeutics have on hand?

What is Hemab Therapeutics’s dividend yield?

Premium Investing Services